The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurence of p63 gene amplification

Journal of Pathology

Volumn 206, Issue 3, 2005, Pages 337-345

  Pruneri, Giancarlo ^a,b   Fabris, Sonia ^c   Dell'Orto, Patrizia ^a   Biasi, Maria Olivia ^a   Valentini, Stefano ^a   Del Curto, Barbara ^a   Laszlo, Daniele ^a   Cattaneo, Laura ^a   Fasani, Roberta ^a   Rossini, Laura ^c   Manzotti, Michela ^a   Bertolini, Francesco ^a   Martinelli, Giovanni ^a   Neri, Antonio ^c   Viale, Giuseppe ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

FISH; Follicular lymphomas; Immunohistochemistry; p63; RT PCR

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; ISOPROTEIN; MESSENGER RNA; PROTEIN ANTIBODY; PROTEIN BCL 6; PROTEIN P40; PROTEIN P63; RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CHROMOSOME 3Q; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOMA CELL; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TRANSACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; IN SITU NICK-END LABELING; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 21344449113     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1787     Document Type: Article

References (27)

1. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: over-lapping and distinct functions. J Cell Sci 2000;113:1661-1670.
2. Yang A, Kaghad M, Wang Y, Gillet E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-316.
3. Nishi H, Isaka K, Sagawa Y, Usuda S, Fujito A, Ito H, et al. Mutation and transcription analyses of the p63 gene in cervical carcinoma. Int J Oncol 1999;15:1149-1153.
4. Sunahara M, Shishikura T, Takahashi M, Todo S, Yamamoto N, Kimura H, et al. Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene 1999;18:3761-3765.
5. Tani M, Shimizu K, Kawahara C, Kohno T, Ishimoto O, Ikawa S, et al. Mutation and expression of the p51 gene in human lung cancer. Neoplasia 1999;1:71-79.
6. Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999;59:4165-4169.
7. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000;97:5462-5467.
8. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000;60:3370-3774.
9. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25:1054-1060.
10. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 2001;32:1157-1165.
11. Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001;32:479-486.
12. Pruneri G, Pignataro L, Manzotti M, Carboni N, Ronchetti D, Neri A, et al. p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 downregulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 2002; 82:1327-1334.
13. Swerdlow SH, Berger F, Isaacson PI, Muller-Hermelink HK, Nathwani BN, Piris MA, Harris NL. Follicular lymphoma. In Tumours of the Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). IARC Press: Lyon, 2001; 162-167.
14. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.
15. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003;102:1443-1448.
16. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501.
17. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427.
18. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
19. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-1775.
20. Chilosi M, Zamo A, Brighenti A, Malpeli G, Montagna L, Piccoli P, et al. Constitutive expression of ΔN-p63α isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003; 443:175-183.
21. Pruneri G, Fabris S, Fasam R, Del Curto B, Capella C, Pozzi B, et al. Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. J Pathol 2003; 200:596-601.
22. Husson H, Carideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99:282-289.
23. Aster JC, Longtine JA. Detection of BCL2 rearrangements in follicular lymphoma. Am J Pathol 2002;160:759-763.
24. Lopez-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999;93:3081-3087.
25. Lai R, Arber DA, Chang KL, Wilson CS, Weiss LM. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol 1998;11:864-869.
26. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63:7113-7121.
27. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, van der Veen A, Haralambieva E, van den Berg A, et al. Follicular lymphoma grade 3B includes three cytogenefically defined subgroups with primary t(14; 18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003;101:1149-1154.